Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

To join this study, people must have pancreatic cancer that has spread to other parts of the body and have not yet been treated for this spread. If you've had surgery or chemotherapy/radiotherapy for your pancreatic cancer in the past, that's generally okay, as long as it was completed at least a year ago and any side effects have settled down. Your general health and fitness, as assessed by your doctor, are also important.

There are some reasons why someone might not be able to join. For instance, if you've had specific types of pancreatic cancer treatment that didn't fully remove the cancer but wasn't spread, or if the cancer has spread to your brain or the lining of your brain, you wouldn't be eligible. Also, if you've previously taken a similar type of drug to quemliclustat, you wouldn't be able to participate. The study doctors need to make sure it's safe for you to take part given your full medical history.

If you join this study, you'll be randomly assigned to one of two groups, like flipping a coin. You'll either receive the new drug (quemliclustat) plus standard chemotherapy, or a dummy drug (placebo) plus standard chemotherapy. Neither you nor your doctor will usually know which group you are in.

You will have regular appointments and tests, including scans (like CT or MRI) to check on your cancer, blood tests, and physical examinations. These visits will help doctors monitor your health, how you are responding to treatment, and any side effects you might experience. The total duration of your participation will depend on how you respond to the treatment, but monitoring will continue regularly after treatment stops.